PEGS 2017 Speakers


Plenary Keynote Speakers:

  • Sir Gregory Winter, Ph.D., FRS, Master, Trinity College and Co-Founder and Director, Bicycle Therapeutics
  • Tim Whitehead, Ph.D., Assistant Professor, Chemical Engineering and Materials Science, Michigan State University

Distinguished Faculty:

  • Chloé Ackaert, Ph.D., Post-Doctoral Researcher, Bioengineering Sciences, Camel Antibodies Lab, Cellular and Molecular Immunology, Vrije Universiteit Brussel (VUB)
  • Prasad S. Adusumilli, M.D., F.A.C.S., Associate Attending and Deputy Chief, Thoracic Surgery, Memorial Sloan Kettering Cancer Center
  • Mahiuddin Ahmed, Ph.D., Assistant Attending, Immunotherapies, Pediatrics, Memorial Sloan Kettering Cancer Center
  • Steven Almo, Ph.D., Chairman, Biochemistry, and Professor, Biochemistry and Physiology & Biophysics, Montefiore Medical Center, Albert Einstein College of Medicine
  • Frederick Alt, Ph.D., Charles A. Janeway Professor of Pediatrics, Boston Children’s Hospital; Professor of Genetics, Harvard Medical School; Director, Program in Cellular and Molecular Medicine, Boston Children’s Hospital
  • Galit Alter, Ph.D., Associate Professor, Medicine; Kristine & Bob Higgins MGH Research Scholar; Director, Ragon Institute Imaging Core; Director, Harvard Center for Aids Research Immunology Core
  • Luis Alvarez-Vallina, Ph.D., Associate Professor, Engineering, Aarhus University
  • Zhiqiang An, Ph.D., Professor and Robert A. Welch Distinguished University Chair in Chemistry, University of Texas Health Science Center at Houston
  • Juni Andréll, Ph.D., Researcher, Biochemistry and Biophysics, University of Stockholm
  • Christian Antoni, Ph.D., Vice President, Immunology & Inflammation, Sanofi
  • Philip M. Arlen, M.D., President and CEO, Precision Biologics, Inc.
  • Gai Ayalon, Ph.D., Scientist, Neuroscience, Genentech
  • John Babcook, Ph.D., Senior Vice President, Discovery Research, Zymeworks Inc.
  • Sashikanth Banappagari, Ph.D., Scientist, Formulation Development, Vaccine Research Center, National Institutes of Health
  • Robin Barbour, Head, Antibody and Assay Development, Research, Prothena Biosciences
  • Ishan Barman, Ph.D., Assistant Professor, Mechanical Engineering, Johns Hopkins University
  • Amrik Basran, CSO, Therapeutics, Avacta Life Sciences
  • Nicola Beaucamp, Ph.D., Head, Process Research, Pharma Research and Early Development, Roche Innovation Center
  • Paul Beavis, Ph.D., Senior Postdoctoral Researcher, Cancer Immunotherapy, Peter MacCallum Cancer Centre
  • Roger R. Beerli, Ph.D., CSO, NBE-Therapeutics AG
  • Donald A. Bergstrom, M.D., Ph.D., CMO, Mersana Therapeutics
  • Alison Betts, Ph.D., Associate Research Fellow, Biomedicine Design, Pfizer
  • Michael J. Betenbaugh, Ph.D., Department of Chemical and Biomolecular Engineering, Johns Hopkins University
  • Rudi Beyaert, Ph.D., Vice Department Director, Inflammation Research Center, VIB
  • Tuhin Bhowmik, Ph.D., Scientist I, Formulation, Takeda Vaccines
  • Carl Uli Bialucha, Ph.D., Director, Oncology Biotherapeutics, Novartis Institutes for Biomedical Research, Inc.
  • Murali Bilikallahalli, Ph.D., Senior Director, Ultragenyx Pharmaceuticals
  • John W. Blankenship, Ph.D., Lead Scientist, Molecular Biology & Protein Engineering, Aptevo Therapeutics
  • Adrian Bot, M.D., Ph.D., Vice President, Translational Medicine, Kite Pharma
  • George Bou-Assaf, Ph.D., Scientist, Technical Development, Biogen
  • Andrew M. Bradbury, M.D., Ph.D., Staff Scientist, Biosciences, Los Alamos National Laboratory
  • Dennis Breitspecher, Ph.D., Head of Research and Development – Biochemistry, NanoTemper Technologies, GmbH
  • John S. Bridgeman, Ph.D., Director of Cell Therapy Research, Cellular Therapeutics, Ltd.
  • Lisa Burdette, Laboratory for the Engineering of Membrane Proteins and Protein Membranes, Department of Chemical and Biomolecular Engineering, Northwestern University
  • Marco Cacciuttolo, Ph.D., Project Office, Batavia Biosciences
  • Nico Callewaert, Ph.D., Director, VIB Medical Biotechnology Center, Ghent University
  • Julio A. Camarero, Ph.D., Associate Professor, Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California
  • Uwe Carl, Ph.D., Head, Protein Production, Strep-Tag Products and Proteins, IBA Lifesciences
  • Ralf Joe Carrillo, Ph.D., Senior Scientist, Physical Chemistry, AbbVie
  • Jennifer Cha, Ph.D., Norviel Associate Professor, Chemical & Biological Engineering, University of Colorado, Boulder
  • Kartik Chandran, Ph.D., Professor, Microbiology and Immunology, Harold and Muriel Block Faculty Scholar in Virology, Albert Einstein College of Medicine
  • Smita Chandran, Ph.D., Senior Research Scientist, Memorial Sloan Kettering Cancer Center
  • Paul B. Chapman, M.D., Medical Oncologist, Memorial Sloan Kettering Cancer Center
  • Ravi Chari, Ph.D., Vice President, Chemistry & Biochemistry, ImmunoGen, Inc.
  • Nai-Kong V. Cheung, M.D., Ph.D., Enid A. Haupt Chair, Pediatric Oncology, Memorial Sloan Kettering Cancer Center
  • Aaron Chevalier, Ph.D., CSO, Virvio, Inc.; Translational Investigator, Institute of Protein Design, University of Washington
  • Yite Robert Chou, Ph.D., Principal Scientist, Merck
  • Vijay Chudasama, Ph.D., Lecturer, Organic Chemistry and Chemical Biology, University College London
  • Steven Coats, Ph.D., Vice President, R&D, MedImmune
  • Jennifer Cochran, Ph.D., Hitachi America Associate Professor, Bioengineering and Chemical Engineering, Stanford University
  • Luis G. Cuello, Ph.D., Associate Professor, Cell Physiology and Molecular Biophysics and Center for Membrane Protein Research, Texas Tech University Health Sciences Center
  • Michael A. Curran, Ph.D., Assistant Professor, Immunology, MD Anderson Cancer Center
  • Brendan Curti, Director, Genitourinary Oncology Research, Immunotherapy Clinical Program, Providence Medical Group
  • Charles S. Craik, Ph.D., Professor, Pharmaceutical Chemistry, University of California, San Francisco
  • Steven Cramer, Ph.D., Professor, Rensselaer Polytechnic Institute
  • James E. Crowe, Jr., M.D., Professor, Pathology, Microbiology & Immunology, Vanderbilt University
  • Niklas Czeloth, Ph.D., Head, Biosciences, Biosimilars, Boehringer Ingelheim GmbH
  • Jostein Dahle, Ph.D., CSO, Nordic Nanovector ASAc
  • Paul Dalby, Ph.D., Professor of Biochemical Engineering and Biotechnology, University College London
  • Amita Datta-Mannan, Ph.D., Research Advisor and Group Leader, Eli Lilly and Company
  • Patrick S. Daugherty, Ph.D., President & CSO, Serimmune Inc.; Adjunct Professor, University of California, Santa Barbara
  • Marco Davila, M.D., Ph.D., Associate Member, Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute
  • Jonathan H. Davis, Ph.D., Principal Scientist, Protein Design, Bristol-Myers Squibb
  • Tom Davis, M.D., Executive Vice President and CMO, Celldex Therapeutics Inc.
  • Jeremy Derrick, Ph.D., Professor, Molecular Microbiology, University of Manchester
  • John R. Desjarlais, Ph.D., CSO, Xencor, Inc.
  • Adi Diab, M.D., Assistant Professor, MD Anderson Cancer Center
  • Rakesh Dixit, Ph.D., DABT, Vice President, R&D, Global Head, Biologics Safety Assessment, Translational Sciences, MedImmune
  • Bart De Goeij, Scientist, Antibody Science, GenMab A.V.
  • Gael Debauve, Ph.D., Associate Director, Bioassays, UCB
  • Cesar de la Fuente, Ph.D., Postdoctoral Associate, Biological Engineering, MIT/Broad Institute of MIT and Harvard
  • Julio Delgado, MD, Medical Director and Section Chief, Immunology Division, ARUP Laboratories; Associate Professor, Pathology, University of Utah School of Medicine
  • Stephen J. Demarest, Ph.D., Senior Research Advisor, Protein and Antibody Engineering, Lilly Biotechnology Center
  • Ratmir Derda, Ph.D., Assistant Professor, Chemistry, University of Alberta
  • John Desjarlais, Ph.D., CSO, Xencor
  • Craig D. Dickinson, Ph.D., Senior Research Advisor, AME, Eli Lilly and Company
  • Anaëlle Dos Santos, Ph.D., Head, Bioanalytical Development, NovImmune
  • Jonathan Drachman, M.D., CMO and Executive Vice President, Research and Development, Seattle Genetics
  • Keren Drori, Ph.D., Product Manager II, Protein Science, Takara Bio USA
  • Zhimei Du, Ph.D., Senior Principal Scientist, Merck & Company, Inc.
  • Jakob Dupont, Ph.D., Senior Vice President, Oncomed Pharmaceutical
  • Scott J. Dylla, Ph.D., Vice President, Research & Development, CSO, AbbVie Stemcentrx, LLC
  • Michael Dyson, Ph.D., CTO, IONTAS, Ltd.
  • Aris N. Economides, Ph.D., Executive Director; Genome Engineering Technologies, and Skeletal Diseases TFA, Co-Founder & Head of Functional Modeling; Regeneron Genetics Center, Regeneron Pharmaceuticals, Inc.
  • Sabine Eichling, Senior Scientist, Abbvie
  • Sam Ellis, Vice President & Biochemist, Thomson Instrument Company
  • Peter Ellmark, Ph.D., Principal Scientist, Research & Development, Alligator Bioscience
  • Peter Emtage, Ph.D., CSO, Cell Design Labs
  • Elizabeth England, Scientist, Antibody Discovery and Protein Engineering, MedImmune
  • James A. Ernst, Ph.D., Senior Scientist, gRED, Protein Chemistry and Neuroscience, Research and Early Development, Genentech, Inc.
  • Seth Ettenberg, Ph.D., CSO, Unum Therapeutics
  • Rachel Ettinger, Ph.D. Senior Scientist Respiratory, Inflammatory, and Autoimmune Diseases, MedImmune
  • David Gilham, Ph.D., Vice President, Research & Development, Celyad S.A.
  • Soldano Ferrone, M.D., Ph.D., Division of Surgical Oncology, Surgery, Massachusetts General Hospital
  • Dina Finan, Ph.D., Product Manager, Unchained Labs
  • Mark T. Fisher, Ph.D., Professor, Biochemistry and Molecular Biology, University of Kansas Medical School
  • Fredrik Frejd, Ph.D., CSO, Affibody AB
  • Matthew J. Frigault, M.D., Clinical Fellow in Medicine, Dana-Farber Cancer Institute
  • Yang-Xin Fu, M.D., Ph.D., Mary Nell and Ralph B. Rogers Professorship in Immunology, University of Texas, Southwestern Medical Center
  • Jim Freeth, Managing Director, Retrogenix Limited
  • Ricarda Friebe, MSc, Scientific Assistant, Institute of Bioprocess Engineering, Friedrich-Alexander-University Erlangen-Nürnberg
  • Anja Fritsch, Ph.D., CSO, Solvias
  • Terry J. Fry, M.D., Investigator and Head, Hematologic Malignancies Section, Pediatric Oncology Branch, National Cancer Institute
  • Gayatri Ganeshan, Scientist, Biologics and Vaccines, Merck
  • Robert F. Garry, Ph.D., Professor, Microbiology & Immunology, Tulane Medical School; Co-Founder, Zalgen Labs
  • John Garza, Ph.D., Development Scientist II, Analytical Sciences, Alexion Pharmaceuticals
  • Kurt Gehlsen, Ph.D., Vice President and CSO, Therapeutics, Research Corporation Technologies, Inc.
  • Tariq Ghayur, Ph.D., Distinguished Research Fellow, Biologics, AbbVie Bioresearch Center, Inc.
  • Maloy Ghosh, Ph.D., CSO, Zumutor Biologics
  • Pierre-Alain Girod, Ph.D., CSO, Selexis
  • Shalom Goldberg, Ph.D., Senior Scientist, Johnson & Johnson
  • Theresa J. Goletz, Ph.D., Global Head, NBE Drug Disposition, QPD, EMD Serono
  • Ulrich Göpfert, Ph.D., Principal Scientist, Cell Line & Molecular Development, Roche Innovation Center
  • Sean Gray, Ph.D., Senior Scientist, PAI Life Sciences
  • Karl E. Griswold, Ph.D., Associate Professor, Thayer School of Engineering, Dartmouth
  • Jijie Gu, Ph.D. Research Fellow, Immunology & Oncology Biologics at Global Biologics, AbbVie
  • Chandrasekhar Gurramkonda, Ph.D., Research Assistant Professor, Chemical, Biochemical and Environmental Engineering, University of Maryland
  • Andrew Hanneman, Associate Director, Mass Spectrometry, Charles River
  • Haruki Hasegawa, Ph.D., Principal Scientist, Therapeutic Discovery, Amgen, Inc.
  • Ronald Herbst, Ph.D., Vice President and Head, Oncology Research, MedImmune
  • Guy Hermans, CSO, Isogenica Limited
  • John Hickey, Ph.D., Assistant Director, Macromolecule and Vaccine Stabilization Center, University of Kansas
  • Oliver Hill, Ph.D., Vice President, Molecular Biology, APOGENIX AG
  • Mitchell Ho, Ph.D., Chief, Antibody Therapy Section, Laboratory of Molecular Biology, National Cancer Institute, NIH
  • Björn Hock, Ph.D., Senior Director, Global Head ADCs and Targeted NBE Therapeutics, Merck KGaA
  • Josefin-Beate Holz, Ph.D., Bioneer-Consulting, part of NDA
  • Axel Hoos, M.D., Ph.D., Senior Vice President, Therapeutic Area Head for Oncology R&D, GlaxoSmithKline Pharmaceuticals, Inc.
  • Walter Hoyer, Ph.D., Manager, Statistics, GSK Vaccines
  • John Hunt, Ph.D., Professor, Biological Sciences, Columbia University
  • David Humphreys, Ph.D., Director and Head, Protein Sciences, UCB NewMedicines
  • Rafiq Islam, Ph.D., Senior Director, Bioanalytical Services, Celerion, Inc.
  • Yoshi Itoh, Ph.D., Associate Professor and Principal Investigator, Cell Migration Group, Kennedy Institute of Rheumatology, University of Oxford
  • Bent Jakobsen, Ph.D., CSO, Immunocore Ltd.
  • Darshana Jani, Ph.D., Senior Manager, Global Assay Lead, Pfizer
  • Donald Jarvis, Ph.D., Professor, Molecular Biology, University of Wyoming
  • Jeliazko Jeliazkov, Research Assistant, Molecular Biophysics, Johns Hopkins University
  • Karin Jooss, Ph.D., CSO, Gritstone Oncology, Inc.
  • Sujith K Joseph, Ph.D., Staff Scientist, Department of Pediatrics Center for Cell and Gene Therapy Baylor College of Medicine
  • Vanessa Jully, Ph.D., Scientist, Research & Development, GlaxoSmithKline
  • Ravi C. Kalathur, Ph.D., New York Structural Biology Center, New York Consortium on Membrane Protein Structure (NYCOMPS)
  • Paul Kang, CSO, Discovery Research, Innovative Targeting Solutions
  • Guna Kannan, Ph.D., Director Antibody Engineering & CMC, Affinita Biotech
  • Raghuraman Kannan, Ph.D., Associate Professor, Radiology and Biological Engineering, School of Medicine, University of Missouri
  • Shefali Kakar, Ph.D., Executive Director, Head, Oncology, Clinical Pharmacology, Novartis
  • Azad Kaushik, DVM, D.Sc., Associate Professor, College of Biological Science, Department of Molecular and Cellular Biology, University of Guelph
  • Saad Kenderian, M.D., Assistant Professor of Medicine and Oncology, Hematology, Mayo Clinic College of Medicine
  • Randal Ketchem, Ph.D., Vice President, Molecular Design, Just Biotherapeutics
  • Hubert Kettenberger, Ph.D., Senior Principal Scientist, Protein Analytics, Roche Pharma Research & Early Development, Roche Innovation Center Penzberg
  • Maura Kibbey, Ph.D., Director, Science & Standards, Global Biologics, United States Pharmacopeial Convention
  • Takanori Kigawa, Ph.D., Team Leader, Quantitative Biology Center (QBiC), RIKEN
  • Chava Kimchi-Sarfaty, Ph.D., Research Chemist, Principal Investigator, Division of Hematology Research and Review, FDA/CBER/OBRR
  • Christian Klein, Ph.D., Discovery Oncology oDTA, Pharma Research and Early Development (pRED), Roche Glycart AG
  • Hans Klingemann, M.D., Ph.D., Vice President, Research & Development, NantKwest, Inc.
  • David M. Knipe, Ph.D., Department of Microbiology and Immunobiology, Harvard Medical School
  • Emilee Knowlton, Ph.D., Immunology Sales Specialist, ProImmune
  • Shohei Koide, Ph.D., Professor, Biologics Design, Langone Medical Center, New York University
  • Natalia Kozhemyakina, Ph.D., Head, Bioassay Laboratory, Analytical Development Department, BIOCAD
  • Roland Kontermann, Ph.D., Professor of Biomedical Engineering, Institute of Cell Biology and Immunology, University of Stuttgart
  • Thomas Krey, Ph.D., Institute of Virology, Structural Virology Group, Hannover Medical School
  • Torsten Kuiper, Principal Scientist, BTDM Integrated Biologics Profiling, Novartis Pharma AG
  • Vinodh Kurella, Ph.D., Senior Scientist, Protein Engineering, ImmunoOncology Division, Intrexon Corporation
  • David Laidlaw, CEO, Kuhner Shaker, Inc.
  • Annie Lam, Ph.D., Scientist II, Antibody Engineering, MacroGenics, Inc.
  • John Lambert, Ph.D., Executive Vice President and Distinguished Research Fellow, ImmunoGen
  • Ramil Latypov, Ph.D., Associate Director, Research & Development, Sanofi Genzyme
  • Hans-Georg Lerchen, Ph.D., Principal Scientist, Drug Discovery, MedChem, Bayer AG
  • Cammie Lesser, M.D., Ph.D., d’Arbeloff MGH Research Scholar, Associate Professor, Medicine, Microbiology and Immunobiology, Massachusetts General Hospital/Harvard Medical School
  • Randolph P. Lewis, Ph.D., USTAR Professor, Biology / Synthetic Bio-Manufacturing, Utah State University
  • Raquel Lieberman, Ph.D., School of Chemistry & Biochemistry, Georgia Institute of Technology
  • Shihua Lin, Ph.D., Senior Scientist, Analytical Biotechnology Development, MedImmune LLC
  • Bin Liu, Ph.D., Professor, Anesthesia, University of California, San Francisco
  • Curtis Lockshin, Ph.D., Chief Scientific Officer, Xenetic Biosciences, Inc. 
  • David Lowe, Ph.D., Director, R&D, Antibody Discovery and Protein Engineering, MedImmune Ltd.
  • Linlin Luo, Ph.D., Senior Research Investigator, BMS
  • Mark Ma, Ph.D., Senior Director, Bioanalytical Development, Alexion Pharmaceuticals
  • David G. Maloney, M.D., Ph.D., Medical Director, Cellular Immunotherapy; Leonard and Norma Klorfine Endowed Chair for Clinical Research, Fred Hutchinson Cancer Research Center; Professor, Medicine, Oncology, University of Washington
  • Tony Manning, Ph.D., Vice President, Research, Momenta Pharmaceuticals
  • Wayne Marasco, Professor, Cancer Immunology and Virology, Dana-Farber Cancer Institute
  • Paolo Marcatili, Ph.D., Assistant Professor, Bio and Health Informatics, Technical University of Denmark
  • Erminia Massarelli, M.D., Ph.D., MS, Associate Clinical Professor, Medical Oncology and Therapeutics Research, City of Hope
  • Paul Matsudaira, Ph.D., Professor, Dept. of Biological Sciences, National University of Singapore
  • Jon R. McDaniel, Ph.D., Georgiou Laboratory, Chemical Engineering, Biomedical Engineering, Molecular Biosciences; Institute for Cellular and Molecular Biology, University of Texas at Austin
  • Yvonne McGrath, Ph.D., CSO, Complix NV
  • J. Joseph Melenhorst, Ph.D., Director, Product Development & Correlative Sciences Laboratories (PDCS); Adjunct Associate Professor, Center for Cellular Immunotherapies, University of Pennsylvania
  • Tatyana Mezhebovsky, Ph.D., Principal Scientist, BioFormulations Development, Sanofi
  • Jennifer Michaelson, Ph.D., Executive Program Leader, Senior Director of Preclinical Development, Preclinical Development, Jounce Therapeutics Inc.
  • Jeffrey S. Miller, M.D., Professor, Medicine, Division of Hematology, Oncology and Transplantation; Deputy Director, Masonic Cancer Center, University of Minnesota
  • Stephen D. Miller, Ph.D., Professor, Microbiology-Immunology and Dermatology, Northwestern University
  • David Meininger, Chief Business Officer, Trianni, Inc.
  • Christoph Merten, Ph.D., Group Leader Microfluidics, European Molecular Biology Laboratory (EMBL)
  • Marissa Mock, Ph.D., Senior Scientist, Therapeutic Discovery; Biologics, Amgen
  • Joerg Moelleken, Ph.D., Senior Scientist, Roche Pharmaceutical Research and Early Development, Large Molecule Research, Roche Innovation
  • Ekkehard Moessner, Ph.D., Head, Protein Engineering, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich
  • Vera Molkenthin, Ph.D., Chief Scientist, AbCheck s.r.o.
  • Aaron Morris, Senior Director, Research, Checkmate Pharmaceuticals, Inc.
  • Barry A. Morse, Ph.D., Principal Research Scientist, Janssen Research and Development
  • Masaru Muraoka, Ph.D., Research Scientist, Chugai Pharmabody Research PTE. LTD.
  • Peter Neubauer, Ph.D., Professor, Bioprocess Engineering, Biotechnology, Technische Universität Berlin (TU Berlin)
  • Ahuva Nissim, Ph.D., Associate Professor, Antibody and Therapeutic Engineering, William Harvey Research Institute, Queen Mary University of London
  • Nili Ostrov, Ph.D., Research Fellow, Genetics, Harvard Medical School
  • Tadas Panavas, Ph.D., Associate Director, Discovery Research, Alexion Pharmaceuticals, Inc.
  • Peter Park, Ph.D., Vice President, Oncology Research, Bicycle Therapeutics
  • Edward F. Patz, Jr., M.D., James and Alice Chen Professor, Radiology; Professor, Pharmacology and Cancer Biology, Radiology, Duke University Medical Center
  • Bradley L. Pentelute, Ph.D., Professor, Chemistry, Massachusetts Institute of Technology
  • Juergen M. Plitzko, Ph.D., Head, TEM, Molecular Structural Biology, Max Planck Institute of Biochemistry
  • Horacio G. Nastri, Ph.D., Senior Director, Antibody Biotherapeutics, Incyte Corporation
  • Dario Neri, Ph.D., Professor, Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zurich), and Co-Founder, Philogen
  • Vincent Noireaux, Ph.D., School of Physics and Astronomy, University of Minnesota
  • Natko Nuber, Ph.D., Laboratory Head, BTDM-BPD, Novartis Biologics R&D, Novartis
  • Michael Oropallo, Ph.D., Associate Scientist, Postdoctoral Fellow, Safety Assessment & Laboratory Animal Resources, Merck
  • Andreas Pahl, Ph.D., CSO, Heidelberg Pharma
  • Michelle Palmer, Ph.D., Director, Bioanalytical Science, ImmunoGen
  • Rajita Pappu, Ph.D., Senior Scientist, Genentech
  • Belinda Pastrana, Ph.D., Professor, Chemistry, University of Puerto Rico Mayaguez, Puerto Rico
  • James Patterson, Ph.D., Senior Scientist, Project Leader, Antibody Technologies and Chemical Biology, Sorrento Therapeutics, Inc.
  • Pedro Paz., Ph.D., BR US Lead Discovery, Immunoassay/Immunoprofiling Group, Bayer HealthCare
  • David Pearlman, Senior Principal Scientist, Schrödinger
  • Josh T. Pearson, Ph.D., Principal Scientist, Pharmacokinetics & Drug Metabolism, Amgen
  • Bradley L. Pentelute, Ph.D., Pfizer Laubach Career Development Assistant Professor, Chemistry, Massachusetts Institute of Technology
  • Michael Postow, M.D., Medical Oncologist, Department of Medicine, Memorial Sloan Kettering Cancer Center
  • Kathleen Pratt, Ph.D., Associate Professor, Department of Medicine, Uniformed Services University
  • Ming Proschitsky, Ph.D., Senior Scientist, Research, Proclara Biosciences
  • James R. Prudent, Ph.D., President & CEO, Centrose
  • Yan Qu, Ph.D., Senior Principal Scientist, Pfizer
  • Isam Qahwash, Ph.D., Manager, Bioassay Development, Molecular and Analytical Development, Bristol-Myers Squibb
  • Christophe Quéva, Ph.D., CSO, iTeos Therapeutics SA
  • Francisco Quintana, Ph.D. Associate Scientist, Brigham and Women’s Hospital; Associate Professor, Neurology, Harvard Medical School
  • Anacelia Ríos Quiroz, Ph.D., Group Leader, Particle Lab, Pharma Technical Development Europe (Biologics) Analytics, F. Hoffmann-La Roche Ltd.
  • Christoph Rader, Ph.D., Associate Professor, Immunology, The Scripps Research Institute
  • Laszlo Radvanyi, Ph.D., Senior Vice President and Global Head of The Immuno-Oncology Translational Innovation Platform at EMD Serono (a business of Merck KGaA, Darmstadt, Germany)
  • Reema Raghavendra, Scientist, AbbVie
  • Miki Rahat, D.Sc., Assistant Professor, Immunology, Technion; Director, Research Laboratories, Carmel Medical Center
  • G. Jonah Rainey, Ph.D., Senior Scientist, ADPE, MedImmune, LLC
  • Sai Reddy, Ph.D., Assistant Professor, Biosystems Science and Engineering, ETH Zurich
  • Joerg Regula, Ph.D., Head of Functional Characterization, Roche
  • Janice M. Reichert, Ph.D., Executive Director, The Antibody Society and Editor-in-Chief, mAbs
  • Ed Reilly, Ph.D., Senior Research Fellow, Oncology Discovery, AbbVie
  • Yoram Reiter, Ph.D., Professor & Head, Laboratory of Molecular Immunology, Technion-Israel Institute of Technology
  • Sarah Richman, M.D., Ph.D., Instructor, Cancer Center, The Children’s Hospital of Philadelphia
  • Christopher J. Roberts, Ph.D., Professor, Chemical & Biomolecular Engineering, University of Delaware
  • Johan Rockberg, Ph.D., Assistant Professor, Proteomics and Nanobiotechnology, KTH - Royal Institute of Technology
  • Christine Rothe, Ph.D., Vice President, Discovery & Alliance Management, Pieris Pharmaceuticals GmbH
  • Michael Rosenzweig, Ph.D., Executive Director, Oncology Discovery, Merck Research Labs
  • Sharon Rosovsky, Ph.D., Assistant Professor, Chemistry and Biochemistry, University of Delaware
  • Gargi Roy, Ph.D., Scientist, MedImmune
  • Kris F. Sachsenmeier, Ph.D., Associate Director, Translational Sciences, AstraZeneca
  • Jason Sagert, Ph.D., Senior Scientist II, Oncology, CytomX Therapeutics
  • Mika Sakurai, Ph.D., Biologics Discovery Dept., Chugai Pharmaceutical Co., Ltd.
  • Hardeep Samra, Ph.D., Senior Scientist, Formulation Sciences, MedImmune
  • Thomas Sandal, Ph.D., Vice President, Preclinical Development and Protein Engineering, Crescendo Biologics Ltd.
  • Puja Sapra, Ph.D., Vice President and CSO, Target Therapeutics Unit, Oncology Research & Development, Pfizer, Inc.
  • David Satijn, Ph.D., Director, New Antibody Products, Genmab
  • Jeffrey G. Saven, Ph.D., Professor, Chemistry, University of Pennsylvania
  • Guido Seidel, Managing Director, Operations, Wacker Biotech GmbH
  • Kathy Seidl, Ph.D., Director, Immunotherapy, bluebird bio
  • Oliver Seifert, Ph.D., Post-Doc, Institute of Cell Biology and Immunology, University of Stuttgart
  • Saurabh Sen, Ph.D., Principal Scientist, Boehringer Ingelheim Pharmaceuticals, Inc.
  • Dolores Schendel, Ph.D., CEO and CSO, Medigene AG
  • Peggy Scherle, Ph.D., Vice President, Preclinical Pharmacology, Incyte Corporation
  • Justin M. Scheer, Ph.D., Director, Antibody Engineering, Boehringer Ingelheim Pharmaceuticals, Inc.
  • Volker Schellenberger, Ph.D., President and CEO, Amunix
  • Stefan Schmidt, Ph.D., M.B.A., Vice President, Process Science and Production, Rentschler Biotechnology
  • Jonathan Schneck, M.D., Ph.D., Professor, Pathology Medicine and Oncology, Johns Hopkins University
  • W. Mike Schopperle, Ph.D., CEO, CureMeta LLC
  • Taylor Schreiber, M.D., Ph.D., Scientific Founder, R&D, Shattuck Labs, Inc.
  • Charles Sentman, Ph.D., Director, Center for Synthetic Immunity, The Geisel School of Medicine, Dartmouth College
  • Andrew Sewell, Ph.D., Distinguished Research Professor and Wellcome Trust Senior Investigator, Cardiff University School of Medicine
  • Lu Shan, Ph.D., Scientist II, Antibody Discovery & Protein Engineering, MedImmune/AstraZeneca
  • Whitney Shatz, MS, Senior Scientific Researcher, Genentech
  • Anthony Shock, Ph.D., Director, Immunology Portfolio, UCB
  • Harpreet Singh, Ph.D., President & CEO, Immatics US, Inc.
  • Arne Skerra, Ph.D., Professor, Technische Universität Munich; and and Chairman & Founder, XL-protein GmbH
  • Matthew Sleeman, Ph.D., Executive Director, Immunology & Inflammation, Regeneron Pharmaceuticals, Inc.
  • Eric Smith, Ph.D., Associate Director, Bispecifics, Regeneron Pharmaceuticals
  • Ernest S. Smith, Ph.D., Senior Vice President, Research & Chief Scientific Officer, Vaccinex, Inc.
  • Oliver Spadiut, Ph.D., Principal Investigator, Biochemical Engineering, Vienna University of Technology
  • Julian Spallholz, Ph.D., Professor, Nutritional Biochemistry, Nutritional Sciences, Texas Tech University
  • Jamie Spangler, Ph.D., Postdoctoral Fellow, Garcia Lab, Molecular & Cellular Physiology and Structural Biology, Stanford University School of Medicine
  • Dirk Spitzer, Ph.D., Assistant Professor, Surgery, Washington University School of Medicine
  • Tom Spitznagel, Ph.D., Senior Vice President, BioPharmaceutical Development and Manufacturing, MacroGenics, Inc.
  • Priya Sriraman, Ph.D., Principal Investigator, Non-Clinical Safety, Celgene
  • Abhishek Srivastava, Ph.D., Fellow, Surgery Branch, National Cancer Institute, NIH
  • Ammar Sukari, M.D., Assistant Professor, Head and Neck Multi-Disciplinary Team Leader, Department of Oncology, School of Medicine , Wayne State University/Karmanos Cancer Institute
  • Shantanu Sule, Ph.D., Senior Research Scientist, Eli Lilly & Company
  • Ying Sun, Ph.D., Associate Director of Chemistry, Ambrx
  • Rajasekhar Suragani, Ph.D., Associate Director, Acceleron Pharma, Inc. 
  • Michael Szardenings, Ph.D., Group Head, Ligand Development, Fraunhofer Institute for Cell Therapy and Immunology
  • David Teachey, M.D., Associate Professor, Pediatrics, Children’s Hospital of Philadelphia
  • Srivalli Telikepalli, Ph.D., Research Chemist, National Institute of Standards and Technology
  • Peter M. Tessier, Ph.D., Richard Baruch M.D. Career Development Professor, Chemical & Biological Engineering, Rensselaer Polytechnic Institute
  • Christopher D. Thanos, Ph.D., Senior Director, Biotherapeutics Discovery, Halozyme Therapeutics
  • Nels Thorsteinson, Scientific Services Manager, Biologics, Chemical Computing Group
  • Stella Tournaviti, Ph.D., Senior Scientist, Cell Line and Molecular Development, Roche Innovation Center
  • Michael Townsend, Ph.D., Associate Director, Biomarker Discovery OMNI, Genentech
  • Miller Tran, Ph.D., Senior Scientist, Lead Discovery, Verdant Therapeutics, Inc.
  • Martin Treder, Ph.D., CSO, Affimed, NV.
  • Elizabeth M. Topp, Ph.D., Dane O. Kildsig Chair and Department Head, Department of Industrial and Physical Pharmacy, Perdue University
  • Michael Tovey, Ph.D., INSERM Director, Research, Laboratory of Biotechnology & Applied Pharmacology, Ecole Normale Supérieure de Cachan
  • Stella Tournaviti, Ph.D., Senior Scientist, Cell Line and Molecular Development, Roche Innovation Center
  • Corinne Ueberschlag, M.Sc., Fellow, Functional Lead Cell Line Development, Biologics Technical Development and Manufacturing, Novartis AG 
  • Michiel E. Ultee, Ph.D., Principal, Ulteemit BioConsulting, LLC
  • Inna Vainshtein, Ph.D., Principal Scientist, Clinical Pharmacology & DMP, MedImmune LLC
  • Bahram (Bob) Valamehr, Ph.D., MBA, Vice President, Cancer Immunotherapy, Fate Therapeutics Inc.
  • Thomas J. Van Blarcom, Ph.D., Associate Research Fellow, Rinat Laboratories, Bio-Therapeutics Division, Pfizer Inc.
  • Neal Van Hoeven, Ph.D., Senior Scientist, Infectious Disease Research Institute
  • Niels Vande Casteele, Pharm.D., Ph.D., Postdoctoral Fellow, Gastroenterology, University of California, San Diego
  • Bjørn Voldborg, MSc, Director, CHO Cell Line Development, The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark
  • Annelise Vuidepot, Ph.D., Head, Protein Science, Immunocore
  • Piyush M. Vyas, Ph.D., Senior Research Scientist, Bioassay Development, Eli Lilly and Company
  • Mingjie Xie, Co-founder and CEO, Rapid Novor Inc
  • Alexei Yeliseev, Ph.D., Staff Scientist, LMBB, NIH/ NIAAA
  • Andy Yeung, Ph.D., Associate Research Fellow, Rinat-Pfizer
  • Travis S. Young, Ph.D., Principal Investigator, Biology, California Institute for Biomedical Research
  • Ying Qing Yu, Senior Science Manager, Scientific Operations, Waters Corporation
  • Elsa Wagner-Rousset, Ph.D., Senior Scientist, Analytical Chemistry & Mass Spectrometry, Pierre Fabre
  • Steven Walfish, Ph.D., Principal Science & Standards Liaison, USP
  • Jieyi Wang, Ph.D., CEO, Lyvgen Biopharma
  • Stefan Weigand, Ph.D., Head, Large Molecule Research, Roche Pharma Research and Early Development (pRED), F. Hoffmann-La Roche, Ltd.
  • Yingxia Wen, Ph.D., Director, Head, Protein Chemistry, Seqirus
  • Maria Wendt, Ph.D., Head of Science, Biologics, Genedata
  • Damien B. Wilburn, Ph.D. Post-Doctoral Senior Researcher, Genome Sciences, University of Washington
  • Ruud de Wildt, Ph.D., Director, Head, Antibody Selections, Biopharm, GlaxoSmithKline
  • David Winarta, Research Scientist, Global Protein Sciences, AbbVie
  • Seung-Wuk Lee, Ph.D., Professor, Bioengineering, University of California, Berkeley; Faculty Scientist, Biological Systems and Engineering, Lawrence Berkeley National Laboratory
  • David D. Weis, Ph.D., Associate Professor, Pharmaceutical Chemistry, University of Kansas
  • Gregory A. Weiss, Ph.D., Professor, Chemistry, Molecular Biology & Biochemistry, University of California, Irvine
  • Kipp A. Weiskopf, Ph.D., Research Scientist, Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine
  • K. Dane Wittrup, Ph.D., J.R. Mares Professor, Chemical Engineering & Bioengineering, Massachusetts Institute of Technology
  • Martin Wright, Ph.D., Associate Director, Selection Technologies, Bristol-Myers Squibb
  • Herren Wu, Ph.D., Senior Vice President, CTO, MedImmune, LLC.
  • William C. Zamboni, Pharm.D., Ph.D., Associate Professor; Director, TOND2I Lab, University of North Carolina at Chapel Hill
  • Lan Zhang, Ph.D., Infectious Diseases and Vaccines Discovery, MRL, Merck & Co., Inc.
  • Min Zhang, Ph.D., Director, Manufacturing Sciences and Technology, AstraZeneca/MedImmune
  • Eunice Zhou, Ph.D., Associate Adjunct Professor, Anesthesia, University of California, San Francisco
  • Linglong Zou, Ph.D., Director of Experimental Immunology, Biologics Assays and Technology, Teva
  • Zhenping Zhu, M.D., Ph.D., Executive Vice President, Biologics, Kadmon Corporation, LLC

Register Now

View By:

Premier Sponsors

FairJourneyBiologics GenScript-CRO Integral-Molecular_NEW  OmniAbUnchainedLabs